For the quarter ending 2025-09-30, THAR had $5,368,360 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -2,101,838 | -4,396,857 |
| Write-off of deferred offering costs | 92,168 | - |
| Stock based compensation | 527,014 | 778,562 |
| Stock issuance pursuant to services agreement | - | 0 |
| Stock issuance pursuant to termination agreement | 0 | 8,253 |
| Prepaid expenses and other current assets | -106,980 | 150,755 |
| Accounts payable | -111,356 | -4,571 |
| Accrued expenses | -368,137 | -66,163 |
| Net cash used in operating activities | -1,855,169 | -3,831,531 |
| Proceeds from issuance of common stock upon private investment in public equity offerings | 1,225,003 | 2,500,000 |
| Proceeds from issuance of common stock upon registered direct public offerings | 7,090,014 | - |
| Proceeds from issuance of common stock upon at-the-market offerings | 0 | 266,625 |
| Payment of deferred offering costs | 952,725 | 272,246 |
| Proceeds from insurance premium financing liability | 0 | 285,178 |
| Repayment of insurance premium financing liability | 50,164 | 200,638 |
| Repayment of note payable | 88,599 | 64,769 |
| Net cash provided by financing activities | 7,223,529 | 2,514,150 |
| Net cash provided by (used in) investing activities | - | 0 |
| Net increase (decrease) in cash | 5,368,360 | -1,317,381 |
| Cash and cash equivalents at beginning of period | 3,559,361 | - |
| Cash and cash equivalents at end of period | 7,610,340 | - |
Tharimmune, Inc. (THAR)
Tharimmune, Inc. (THAR)